[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 24 of about 24
1. Paschoal RS, Cardilli RN, Arruda D, Simões BP, Souza Cda S: [Subcutaneous panniculitis-like T-cell lymphoma]. An Bras Dermatol; 2009 Jul-Aug;84(4):415-9
Genetic Alliance. consumer health - Subcutaneous panniculitis-like T-cell lymphoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Subcutaneous panniculitis-like T-cell lymphoma].
  • Subcutaneous panniculitis-like T-cell lymphoma is extremely rare and has recently been recognized as a clinicopathological entity.
  • Young female, 17 years old, has complained of subcutaneous nodules and plaques in the limbs and abdomen for three years, accompanied of mild weight loss without other constitutional symptoms.
  • Nodal, visceral and bone marrow involvement was absent, and subcutaneous CD3/CD8 atypical lymphocyte infiltration was observed in the skin sample.
  • Chemotherapy interrupted the onset of new lesions and led to remission in the 8-month follow-up.
  • Immunophenotypic and molecular aspects were relevant to the diagnosis and as prognosis makers.
  • [MeSH-major] Lymphoma, T-Cell. Subcutaneous Tissue
  • [MeSH-minor] Adolescent. Female. Humans. Panniculitis / pathology

  • Genetic Alliance. consumer health - Panniculitis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19851676.001).
  • [ISSN] 1806-4841
  • [Journal-full-title] Anais brasileiros de dermatologia
  • [ISO-abbreviation] An Bras Dermatol
  • [Language] por
  • [Publication-type] Case Reports; English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Brazil
  •  go-up   go-down


2. Tzeng HE, Teng CL, Yang Y, Young JH, Chou G: Occult subcutaneous panniculitis-like T-cell lymphoma with initial presentations of cellulitis-like skin lesion and fulminant hemophagocytosis. J Formos Med Assoc; 2007 Feb;106(2 Suppl):S55-9
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Occult subcutaneous panniculitis-like T-cell lymphoma with initial presentations of cellulitis-like skin lesion and fulminant hemophagocytosis.
  • Hemophagocytic syndrome (HPS) may be primary or secondary to malignancies, infections, autoimmune diseases, or drugs.
  • In most cases, HPS occurs at the same time as the diagnosis of underlying malignancy or when it relapses.
  • Treatment with etoposide for fulminant HPS was effective.
  • Four months later, she was admitted again because of newly developed subcutaneous nodules and cellulitis-like skin lesions over her legs.
  • Excisional biopsy of subcutaneous nodule showed subcutaneous panniculitis-like T-cell lymphoma.
  • After etoposide, solumedrol, cytosine arabinoside, and cisplatin regimen chemotherapy, both skin lesions and subcutaneous nodules disappeared.
  • In conclusion, for patients presenting with HPS and cellulitis-like skin lesions, occult lymphoma should be considered, which might not be diagnosed for months, even years.
  • Adequate treatment, including steroid and chemotherapy against malignant lymphoma, should be started as soon as possible for patients with fulminant HPS because of its fatal course.


3. Go RS, Wester SM: Immunophenotypic and molecular features, clinical outcomes, treatments, and prognostic factors associated with subcutaneous panniculitis-like T-cell lymphoma: a systematic analysis of 156 patients reported in the literature. Cancer; 2004 Sep 15;101(6):1404-13
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Immunophenotypic and molecular features, clinical outcomes, treatments, and prognostic factors associated with subcutaneous panniculitis-like T-cell lymphoma: a systematic analysis of 156 patients reported in the literature.
  • BACKGROUND: Subcutaneous panniculitis-like T-cell lymphoma (SPTCL) is an uncommon type of skin lymphoma.
  • The natural history, optimal treatment strategy, and prognostic factors associated with this malignancy are not well defined.
  • METHODS: The authors performed a systematic analysis of all patients with SPTCL reported on in the English-language medical literature, with emphasis on specific clinical features, experiences involving the use of radiotherapy and systemic agents, and prognostic factors predictive of treatment response and clinical outcome.
  • Hemophagocytic syndrome (HPS) was a presenting feature in 37% of patients, and > 90% of patients required treatment at diagnosis.
  • Prednisone was used frequently as initial therapy in patients who had less aggressive disease at presentation; however, durable complete remissions (CR) were infrequent.
  • Anthracycline-based chemotherapy regimens were the most commonly used and most effective systemic treatment options, producing long-term CR in approximately 30% of patients.
  • Among patients who received high-dose chemotherapy and stem cell transplantation (HDT-SCT) for refractory or recurrent disease, 92% achieved CR, with a median response duration of > or = 14 months.
  • The presence of HPS at diagnosis and expression of the gamma/delta T-cell receptor (TCR) by tumor cells were associated with poor survival, whereas age was not.
  • Nonetheless, a subgroup of patients with SPTCL can have long-term disease remission following anthracycline-based initial therapy or subsequent HDT-SCT.
  • [MeSH-major] Lymphoma, T-Cell / therapy. Skin Neoplasms / therapy
  • [MeSH-minor] Adolescent. Adult. Aged. Child. Child, Preschool. Combined Modality Therapy. Female. Humans. Immunophenotyping. Infant. Male. Middle Aged. Panniculitis / pathology. Prognosis. Survival Rate. Treatment Outcome

  • Genetic Alliance. consumer health - Panniculitis.
  • Genetic Alliance. consumer health - Subcutaneous panniculitis-like T-cell lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2004 American Cancer Society.
  • (PMID = 15368328.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] United States
  • [Number-of-references] 74
  •  go-up   go-down


Advertisement
4. Wells J, Kosky CA, Scolyer RA, Lee S, Bye PT, Young GA, Davies L: Unusual case of subcutaneous panniculitis-like T-cell lymphoma. Australas J Dermatol; 2004 May;45(2):114-8
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Unusual case of subcutaneous panniculitis-like T-cell lymphoma.
  • An unusual case of subcutaneous panniculitis-like T-cell lymphoma is presented involving multiple organ systems, which eventually culminated in rapid demise from the haemophagocytic syndrome, after an initial protracted course.
  • However, the condition relapsed on attempted prednisone withdrawal in January 2002 and the patient was noted to have developed truncal subcutaneous nodules.
  • Initial skin biopsy revealed lobular panniculitis, with negative microbiological culture.
  • In July 2002, mononeuritis multiplex was diagnosed after the patient presented with paresthesiae and was treated with pulse cyclophosphamide therapy.
  • By November 2002 there was ulceration of the subcutaneous nodules.
  • Repeat skin biopsy revealed subcutaneous panniculitis-like T-cell lymphoma.
  • The clinical manifestations were supportive of an unifying diagnosis of malignancy involving pulmonary, cutaneous and nervous systems.
  • Combination chemotherapy with fludarabine, mitoxantrone and dexamethasone was commenced.
  • Despite maximal supportive therapy the patient succumbed to his disease.
  • [MeSH-major] Lymphoma, T-Cell, Cutaneous / pathology. Panniculitis / pathology. Skin Neoplasms / pathology
  • [MeSH-minor] Adult. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Biopsy. Cryptogenic Organizing Pneumonia / complications. Diagnosis, Differential. Fatal Outcome. Humans. Lung Neoplasms / pathology. Male. Skin Ulcer / pathology


5. Go RS, Gazelka H, Hogan JD, Wester SM: Subcutaneous panniculitis-like T-cell lymphoma: complete remission with fludarabine. Ann Hematol; 2003 Apr;82(4):247-50
Hazardous Substances Data Bank. VIDARABINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Subcutaneous panniculitis-like T-cell lymphoma: complete remission with fludarabine.
  • Subcutaneous panniculitis-like T-cell lymphoma (SPTCL) is an uncommon type of cutaneous lymphoma with an aggressive natural history.
  • It generally carries a poor prognosis despite standard anthracycline-based chemotherapy.
  • The optimum therapy is unknown.
  • His skin ulcers started to heal within 2 weeks of the first cycle of chemotherapy and were completely healed before the fourth cycle.
  • Unfortunately, he died suddenly of unknown cause 3 months after the completion of chemotherapy while remaining in complete remission.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Lymphoma, T-Cell / drug therapy. Vidarabine / analogs & derivatives. Vidarabine / therapeutic use
  • [MeSH-minor] Aged. Humans. Male. Necrosis. Panniculitis / diagnosis. Panniculitis / drug therapy


6. Rojnuckarin P, Nakorn TN, Assanasen T, Wannakrairot P, Intragumtornchai T: Cyclosporin in subcutaneous panniculitis-like T-cell lymphoma. Leuk Lymphoma; 2007 Mar;48(3):560-3
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cyclosporin in subcutaneous panniculitis-like T-cell lymphoma.
  • Subcutaneous panniculitis-like T-cell lymphoma (SPTCL) is a rare form of hematologic malignancy characterized by lesions in subcutaneous fat associated with systemic symptoms.
  • The standard treatment of the disease, currently, is not established, but CHOP or CHOP-like regimens are usually given.
  • Three sustained complete remission for the durations of 8 - 9 months off-treatments.
  • T-cell receptor gene rearrangement revealed polyclonality in 3 cases and monoclonality in 1 case.
  • Our data suggest the benefit of incorporating cyclosporin into the treatment regimen for SPTCL.
  • [MeSH-major] Cyclosporine / therapeutic use. Immunosuppressive Agents / therapeutic use. Lymphoma, T-Cell, Cutaneous / drug therapy. Panniculitis / pathology. Skin Neoplasms / drug therapy
  • [MeSH-minor] Adolescent. Adult. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Cisplatin / therapeutic use. Cyclophosphamide / therapeutic use. Cytarabine / therapeutic use. Doxorubicin / therapeutic use. Etoposide / therapeutic use. Female. Gene Rearrangement, gamma-Chain T-Cell Antigen Receptor. Humans. Male. Methylprednisolone / therapeutic use. Middle Aged. Prednisone / therapeutic use. Prognosis. Remission Induction. Treatment Outcome. Vincristine / therapeutic use

  • Genetic Alliance. consumer health - Panniculitis.
  • Genetic Alliance. consumer health - Subcutaneous panniculitis-like T-cell lymphoma.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • Hazardous Substances Data Bank. CYTARABINE .
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • Hazardous Substances Data Bank. CYCLOSPORIN A .
  • Hazardous Substances Data Bank. METHYLPREDNISOLONE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17454599.001).
  • [ISSN] 1042-8194
  • [Journal-full-title] Leukemia & lymphoma
  • [ISO-abbreviation] Leuk. Lymphoma
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Immunosuppressive Agents; 04079A1RDZ / Cytarabine; 5J49Q6B70F / Vincristine; 6PLQ3CP4P3 / Etoposide; 80168379AG / Doxorubicin; 83HN0GTJ6D / Cyclosporine; 8N3DW7272P / Cyclophosphamide; Q20Q21Q62J / Cisplatin; VB0R961HZT / Prednisone; X4W7ZR7023 / Methylprednisolone; CHOP protocol; ESAP protocol
  •  go-up   go-down


7. Cassis TB, Fearneyhough PK, Callen JP: Subcutaneous panniculitis-like T-cell lymphoma with vacuolar interface dermatitis resembling lupus erythematosus panniculitis. J Am Acad Dermatol; 2004 Mar;50(3):465-9
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Subcutaneous panniculitis-like T-cell lymphoma with vacuolar interface dermatitis resembling lupus erythematosus panniculitis.
  • Lupus erythematosus (LE) panniculitis (LEP) is a form of chronic cutaneous LE most often characterized by erythematous subcutaneous nodules.
  • The histopathology of LEP may be distinctive, allowing a diagnosis even in the absence of any other LE features.
  • Lymphocytic infiltration of the panniculus is termed lymphocytic lobular panniculitis.
  • This entity has been reported in both LEP and subcutaneous panniculitis-like T-cell lymphoma.
  • We describe a 67-year-old woman who presented with multiple dermal and subcutaneous nodules on her legs and hips.
  • Three years after the onset of her disease, ulcerated plaques and nodules developed.
  • At this time a T-cell receptor gene rearrangement was present and subcutaneous panniculitis-like T-cell lymphoma was diagnosed.
  • Despite multiple doses of chemotherapy she died approximately 1 year after diagnosis.
  • Patients with apparent LEP that have atypical lymphocytes in their biopsy specimens should be followed up closely for the development of T-cell malignancy.
  • [MeSH-major] Dermatitis / pathology. Lymphoma, T-Cell / pathology. Panniculitis / pathology. Panniculitis, Lupus Erythematosus / pathology. Skin Neoplasms / pathology
  • [MeSH-minor] Aged. Biopsy. Diagnosis, Differential. Female. Humans


8. Eser B, Altuntas F, Er O, Kontas O, Ferahbas A, Cetin M, Unal A: A case of subcutaneous panniculitis-like T-cell lymphoma with haemophagocytosis developing secondary to chemotherapy. J Eur Acad Dermatol Venereol; 2004 Nov;18(6):713-5
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A case of subcutaneous panniculitis-like T-cell lymphoma with haemophagocytosis developing secondary to chemotherapy.
  • A 45-year-old woman presented with fever, generalized skin lesions and multiple lymphadenopathies.
  • In her past history she had had six courses of cyclophosphamide and cisplatin combination chemotherapy 7 years ago because of an ovarian carcinoma.
  • Skin biopsy showed diffuse subcutaneous infiltration reminiscent of panniculitis but composed of malignant lymphoid cells that were of T lineage.
  • Bone marrow biopsy showed normocellular myeloid tissue with abundant haemophagocytic macrophages.
  • Subcutaneous panniculitis-like T-cell lymphoma with haemophagocytic syndrome was diagnosed.
  • This is the first case reported of subcutaneous panniculitis-like lymphoma occurring secondary to chemotherapy.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / adverse effects. Blood Coagulation Disorders / chemically induced. Lymphoma, T-Cell, Cutaneous / chemically induced. Panniculitis / chemically induced
  • [MeSH-minor] Fatal Outcome. Female. Humans. Middle Aged. Ovarian Neoplasms / drug therapy


9. Au WY, Ng WM, Choy C, Kwong YL: Aggressive subcutaneous panniculitis-like T-cell lymphoma: complete remission with fludarabine, mitoxantrone and dexamethasone. Br J Dermatol; 2000 Aug;143(2):408-10
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Aggressive subcutaneous panniculitis-like T-cell lymphoma: complete remission with fludarabine, mitoxantrone and dexamethasone.
  • Subcutaneous panniculitis-like T-cell lymphoma (SCPTCL) is a rare cutaneous T-cell lymphoma.
  • The optimal treatment of this disease is undefined.
  • Immunophenotyping confirmed a CD8+ cytotoxic T-cell phenotype.
  • The patient was successfully treated with a combination of fludarabine, mitoxantrone and dexamethasone (FND), and has remained in remission 15 months after cessation of treatment.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Lymphoma, T-Cell, Cutaneous / drug therapy. Panniculitis / drug therapy. Skin Neoplasms / drug therapy


10. Ghobrial IM, Weenig RH, Pittlekow MR, Qu G, Kurtin PJ, Ristow K, Ansell SM: Clinical outcome of patients with subcutaneous panniculitis-like T-cell lymphoma. Leuk Lymphoma; 2005 May;46(5):703-8
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinical outcome of patients with subcutaneous panniculitis-like T-cell lymphoma.
  • Subcutaneous panniculitis-like T-cell lymphoma (SPTCL) is a rare form of cytotoxic T-cell lymphoma.
  • The objective of this study was to characterize the clinical presentation, treatment, and prognosis of patients with SPTCL.
  • The median age at diagnosis was 42 years (range 23-80 years) and 15 (71%) were women.
  • Therapy consisted of chemotherapy in 13 (62%) patients, or other therapeutic interventions in 8 (38%) patients, including surgical excision, corticosteroids alone or in combination with either plaquenil, colchicine, hydroxychoroquine, or azathioprine.
  • The median overall survival from diagnosis was 15 months (range 0.1-104 months).
  • The factors associated with an unfavorable disease course were a low white blood cell count or elevated lactate dehydrogenase.
  • Patients treated aggressively with stem cell transplantation appeared to have an improved overall survival.
  • [MeSH-major] Lymphoma, T-Cell, Cutaneous / therapy. Panniculitis / pathology. Skin Neoplasms / therapy
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Female. Humans. Male. Middle Aged. Retrospective Studies. Treatment Outcome

  • Genetic Alliance. consumer health - Panniculitis.
  • Genetic Alliance. consumer health - Subcutaneous panniculitis-like T-cell lymphoma.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16019507.001).
  • [ISSN] 1042-8194
  • [Journal-full-title] Leukemia & lymphoma
  • [ISO-abbreviation] Leuk. Lymphoma
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA97274
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] England
  •  go-up   go-down


11. Chim CS, Loong F, Ng WK, Kwong YL: Use of fludarabine-containing chemotherapeutic regimen results in durable complete remission of subcutaneous panniculitis-like T-cell lymphoma. Am J Clin Dermatol; 2008;9(6):396-8
Hazardous Substances Data Bank. NOVANTRONE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Use of fludarabine-containing chemotherapeutic regimen results in durable complete remission of subcutaneous panniculitis-like T-cell lymphoma.
  • Subcutaneous panniculitis-like T-cell lymphoma (SPTCL) is a rare lymphoma.
  • The optimal therapy for SPTCL is undefined and the results of treatment with anthracycline-containing chemotherapy for aggressive cases have remained poor.
  • The patient achieved complete remission after one course of treatment.
  • FND may be an effective treatment for aggressive SPTCL.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Lymphoma, T-Cell / drug therapy. Panniculitis / pathology. Skin Neoplasms / drug therapy. Vidarabine / analogs & derivatives

  • Genetic Alliance. consumer health - Panniculitis.
  • Genetic Alliance. consumer health - Subcutaneous panniculitis-like T-cell lymphoma.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • Hazardous Substances Data Bank. FLUDARABINE .
  • Hazardous Substances Data Bank. DEXAMETHASONE .
  • Hazardous Substances Data Bank. VIDARABINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18973407.001).
  • [ISSN] 1175-0561
  • [Journal-full-title] American journal of clinical dermatology
  • [ISO-abbreviation] Am J Clin Dermatol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] New Zealand
  • [Chemical-registry-number] 7S5I7G3JQL / Dexamethasone; BZ114NVM5P / Mitoxantrone; FA2DM6879K / Vidarabine; P2K93U8740 / fludarabine
  •  go-up   go-down


12. Hung GD, Chen YH, Chen DY, Lan JL: Subcutaneous panniculitis-like T-cell lymphoma presenting with hemophagocytic lymphohistiocytosis and skin lesions with characteristic high-resolution ultrasonographic findings. Clin Rheumatol; 2007 May;26(5):775-8
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Subcutaneous panniculitis-like T-cell lymphoma presenting with hemophagocytic lymphohistiocytosis and skin lesions with characteristic high-resolution ultrasonographic findings.
  • Subcutaneous panniculitis-like T-cell lymphoma (SPTCL) is an unusual type of skin lymphoma, characterized by subcutaneous soft tissue infiltration with pleomorphic T-cells and benign macrophages that mimic panniculitis.
  • Hemophagocytic lymphohistiocytosis is a rare but potentially fatal disorder which is thought to result from uncontrolled activation and proliferation of T-cells and excessive activation of macrophages.
  • The fever subsided and the ferritin level declined to normal after treatment with oral steroid and etoposide.
  • However, nonremitting high fever and panniculitis-like skin lesions over her back, arm, lower abdominal wall, and bilateral pretibial regions developed 1 month later.
  • A high-resolution ultrasonography revealed thickening of the subcutaneous fat layer with homogeneous hyperechogenicity pattern and poor-defined margin over the skin lesions.
  • An ultrasound-guided excision biopsy of the nodular lesion over left upper arm was performed and the histopathology showed neoplastic cells with hyperchromatic nucleoli, which extended from deep dermis to subcutaneous fat.
  • The immunochemical stain showed a T-cell lineage of tumor cells.
  • SPTCL was diagnosed and the skin lesions subsided gradually after treatment with anthracycline-based combination chemotherapy.
  • [MeSH-major] Lymphohistiocytosis, Hemophagocytic / etiology. Lymphoma, T-Cell / diagnostic imaging. Skin / diagnostic imaging. Skin Neoplasms / diagnostic imaging
  • [MeSH-minor] Adult. Diagnosis, Differential. Female. Humans. Panniculitis / diagnosis. Ultrasonography


13. Yim JH, Kim MY, Kim HO, Cho B, Chung NG, Park YM: Subcutaneous panniculitis-like T-cell lymphoma in a 26-month-old child with a review of the literature. Pediatr Dermatol; 2006 Nov-Dec;23(6):537-40
Genetic Alliance. consumer health - Subcutaneous panniculitis-like T-cell lymphoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Subcutaneous panniculitis-like T-cell lymphoma in a 26-month-old child with a review of the literature.
  • Subcutaneous panniculitis-like T-cell lymphoma is a rare cytotoxic T-cell lymphoma of the skin that preferentially infiltrates the subcutaneous tissue.
  • We report here this lymphoma occurring in a 26-month-old Korean girl.
  • She presented with multiple erythematous subcutaneous nodules on both extremities and her back along with systemic symptoms.
  • She had a protracted course of multiple erythematous subcutaneous nodules for 1 month and a spiking fever was often noted.
  • The histopathologic findings for the subcutaneous nodules were lobular panniculitis-like material that was composed of atypical lymphocytes and histiocytes.
  • The atypical lymphocytes characteristically rimmed individual fat cells in a lace-like pattern and some of the histiocytes showed phagocytosed white blood cells occasionally.
  • She is currently being treated with combination chemotherapy of cyclophosphamide, doxorubicin, vincristine, and prednisolone.
  • [MeSH-major] Lymphoma, T-Cell / diagnosis. Panniculitis / diagnosis. Subcutaneous Tissue / pathology

  • Genetic Alliance. consumer health - Panniculitis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17155994.001).
  • [ISSN] 0736-8046
  • [Journal-full-title] Pediatric dermatology
  • [ISO-abbreviation] Pediatr Dermatol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 14
  •  go-up   go-down


14. Al Zolibani AA, Al Robaee AA, Qureshi MG, Al Nosian H: Subcutaneous panniculitis-like T-cell lymphoma with hemophagocytic syndrome successfully treated with cyclosporin A. Skinmed; 2006 Jul-Aug;5(4):195-7
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Subcutaneous panniculitis-like T-cell lymphoma with hemophagocytic syndrome successfully treated with cyclosporin A.
  • A 17-year-old girl previously in good health presented with a 2-month history of recurrent, high-grade fever; general fatigue; anorexia; a 10-kg weight loss; and multiple, painful, reddish skin lesions on the lower abdomen.
  • Local skin examination revealed multiple erythematous, tender, and firm subcutaneous nodules of variable size (1-2 cm) on the lower abdomen.
  • Prolonged prothrombin time, 26 seconds (normal range 13-16 seconds); prolonged activated partial thromboplastin time, 61 seconds (normal range 26-38 seconds); positive disseminated intravascular coagulation studies evidenced by low fibrinogen, 74 mg/dL (normal range 160-350 mg/dL); and positive fibrinogen degradation products were also noted.
  • CT showed enlarged lymph nodes in the axillary and inguinal areas, bilateral small pleural effusion, moderate hepatosplenomegaly, severe fatty infiltration of the liver, and thickening of lower abdominal subcutaneous tissue.
  • A deep punch biopsy of a nodule from the right lower abdomen revealed lobular panniculitis with atypical lymphocytes and large macrophages with cytophagocytosis ("beanbag" cells) (Figures 3 and 4).
  • T-cell gene rearrangement studies on skin lesions revealed a monoclonal T-cell receptor (gamma-chain) gene rearrangement, supporting the diagnosis of subcutaneous panniculitis-like T-cell lymphoma.
  • On presentation, the initial treatment included 6 U of fresh frozen plasma, 2 U of packed red blood cells, and 2 g IV fibrinogen for 3 consecutive days.
  • The fever and other systemic symptoms and skin lesions resolved within 2 weeks after the treatment.
  • [MeSH-major] Cyclosporine / therapeutic use. Dermatologic Agents / therapeutic use. Immunosuppressive Agents / therapeutic use. Lymphohistiocytosis, Hemophagocytic / complications. Lymphoma, T-Cell, Cutaneous / drug therapy
  • [MeSH-minor] Adolescent. Female. Humans. Panniculitis / drug therapy. Panniculitis / pathology

  • Genetic Alliance. consumer health - Panniculitis.
  • Genetic Alliance. consumer health - Subcutaneous panniculitis-like T-cell lymphoma.
  • Hazardous Substances Data Bank. CYCLOSPORIN A .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16855414.001).
  • [ISSN] 1540-9740
  • [Journal-full-title] Skinmed
  • [ISO-abbreviation] Skinmed
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Dermatologic Agents; 0 / Immunosuppressive Agents; 83HN0GTJ6D / Cyclosporine
  •  go-up   go-down


15. Guizzardi M, Hendrickx IA, Mancini LL, Monti M: Cytotoxic gamma/delta subcutaneous panniculitis-like T-cell lymphoma: report of a case with pulmonary involvement unresponsive to therapy. J Eur Acad Dermatol Venereol; 2003 Mar;17(2):219-22
Hazardous Substances Data Bank. VINCRISTINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cytotoxic gamma/delta subcutaneous panniculitis-like T-cell lymphoma: report of a case with pulmonary involvement unresponsive to therapy.
  • Peripheral subcutaneous panniculitis-like T-cell lymphoma (PSPTCL) is a rare form of cutaneous lymphoma recently proposed as a distinct clinicopathological entity.
  • It usually presents with multiple indurated subcutaneous plaques or tumours, most commonly located on the extremities and trunk and clinically mimicking lobular panniculitis.
  • Finding of TIA-1+ and perforin + cytolytic granules in atypical pleomorphic lymphocytes suggests PSPTCL origin from granular cells of T-cell or natural killer cell phenotype.
  • Cells have a CD3+ CD4+ CD8- or CD3+ CD4- CD8+ T-cell phenotype.
  • Moreover, these lymphomas can express natural killer cell associated antigens, such as CD56, especially in gamma/delta variants.
  • The prognosis of most PSPTCL is poor even when treated with aggressive chemotherapy.
  • This paper reports a case of PCTCL in a young woman with T-cytotoxic differentiation, with rapid progression unresponsive to several treatments.
  • [MeSH-major] Lung Neoplasms / pathology. Lymphoma, T-Cell, Cutaneous / pathology. Panniculitis / pathology. Skin Neoplasms / pathology
  • [MeSH-minor] Adult. Antineoplastic Combined Chemotherapy Protocols. Cyclophosphamide. Doxorubicin. Fatal Outcome. Female. Humans. Killer Cells, Natural / pathology. Prednisone. Vincristine


16. Goldschmidt N, Amir G, Krieger M, Gilead L, Paltiel O: Fatal hemophagocytic syndrome in a patient with panniculitis-like T-cell lymphoma and no clinical evidence of disease. Leuk Lymphoma; 2003 Oct;44(10):1803-6
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Fatal hemophagocytic syndrome in a patient with panniculitis-like T-cell lymphoma and no clinical evidence of disease.
  • Panniculitis-like T-cell lymphoma is an uncommon type of extranodal T-cell lymphoma which presents clinically with subcutaneous nodules.
  • We report a patient with primary subcutaneous disease and initial complete response to combination chemotherapy.
  • The patient experienced an early relapse which responded to salvage chemotherapy.
  • At autopsy there was no evidence of lymphoma in the bone marrow or other organs.
  • We emphasize that a fatal hemophagocytic syndrome can occur despite minimal or even without evidence: of clinically active lymphoma as demonstrated by autopsy in this case.
  • [MeSH-major] Histiocytosis, Non-Langerhans-Cell / etiology. Lymphoma, T-Cell, Cutaneous / complications. Panniculitis / complications. Skin Neoplasms / complications
  • [MeSH-minor] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Fatal Outcome. Female. Humans. Middle Aged. Syndrome

  • Genetic Alliance. consumer health - Panniculitis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 14692537.001).
  • [ISSN] 1042-8194
  • [Journal-full-title] Leukemia & lymphoma
  • [ISO-abbreviation] Leuk. Lymphoma
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  •  go-up   go-down


17. Barrionuevo C, Anderson VM, Zevallos-Giampietri E, Zaharia M, Misad O, Bravo F, Cáceres H, Taxa L, Martínez MT, Wachtel A, Piris MA: Hydroa-like cutaneous T-cell lymphoma: a clinicopathologic and molecular genetic study of 16 pediatric cases from Peru. Appl Immunohistochem Mol Morphol; 2002 Mar;10(1):7-14
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Hydroa-like cutaneous T-cell lymphoma: a clinicopathologic and molecular genetic study of 16 pediatric cases from Peru.
  • Hydroa-like cutaneous T-cell lymphoma (hydroa-like CTCL) is an unusual pediatric malignancy with a poor prognosis.
  • The lesion consists of lymphomatous T-cell infiltration of the skin and subcutis with variable exocytosis and angiocentricity.
  • It has been also called edematous, scarring vasculitic panniculitis and hydroa-like lymphoma.
  • The differential diagnosis includes other cutaneous lymphomas, particularly the cutaneous nasal type T/natural killer-cell lymphoma, mycosis fungoides, precursor T-cell lymphoblastic lymphoma, nonspecific peripheral T-cell lymphoma, cutaneous anaplastic large cell lymphoma, and subcutaneous panniculitic T-cell lymphoma.
  • Chemotherapy and/or radiotherapy had little or no benefit.
  • The lymphoma extended from the epidermis to the subcutis, with frequent angiocentric and periadnexal array.
  • Lymphoma cells were mostly of intermediate size with dense hyperchromatic nuclei, inconspicuous nucleoli, and infrequent mitosis.
  • The lymphoma cells displayed T-cell cytotoxic phenotype.
  • In addition, they were negative for the natural killer cell antigens CD56 and CD57.
  • T-cell receptor gamma (TCRgamma) displayed monoclonal-type rearrangement in four cases studied.
  • Our findings indicate that hydroa-like CTCL is an independent clinicopathologic entity that affects children.
  • Consequently, it should be considered an independent subset of CTCLs and be included as such in the classification of neoplastic diseases of the lymphoid tissues.

  • Genetic Alliance. consumer health - Cutaneous T-Cell Lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11893040.001).
  • [ISSN] 1541-2016
  • [Journal-full-title] Applied immunohistochemistry & molecular morphology : AIMM
  • [ISO-abbreviation] Appl. Immunohistochem. Mol. Morphol.
  • [Language] ENG
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 34
  •  go-up   go-down


18. Kobayashi R, Yamato K, Tanaka F, Takashima Y, Inada H, Kikuchi A, Kumagai MA, Sunami S, Nakagawa A, Fukano R, Fujita N, Mitsui T, Tsurusawa M, Mori T, Lymphoma Committee, Japanese Pediatric Leukemia/Lymphoma Study Group: Retrospective analysis of non-anaplastic peripheral T-cell lymphoma in pediatric patients in Japan. Pediatr Blood Cancer; 2010 Feb;54(2):212-5
Genetic Alliance. consumer health - Peripheral T-cell lymphoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Retrospective analysis of non-anaplastic peripheral T-cell lymphoma in pediatric patients in Japan.
  • BACKGROUND: Reports of non-anaplastic peripheral T-cell lymphoma (PTCL) in pediatric patients are relatively rare.
  • PROCEDURE: We performed a retrospective analysis in patients with PTCL over an 18-year period (1991-2008).
  • There were nine patients with PTCL, not otherwise specified (PTCL-NOS); ten with extranodal NK/T-cell lymphoma, nasal type; one with angioimmunoblastic T-cell lymphoma; and one with subcutaneous panniculitis-like T-cell lymphoma.
  • Initial lesions involved cervical lymph nodes in five patients, and the skin in five patients.
  • Chemotherapy and radiation was administered in 18 and 2 patients, respectively.
  • Among the two patients who did not receive chemotherapy and radiation, one patient died while being treated for HPS but another improved spontaneously.
  • CONCLUSIONS: Generally, the outcome results of conventional chemotherapy for high-risk PTCL are poor in adult patients.
  • [MeSH-major] Lymphoma, T-Cell, Peripheral / epidemiology. Lymphoma, T-Cell, Peripheral / therapy
  • [MeSH-minor] Adolescent. Antineoplastic Combined Chemotherapy Protocols. Child. Child, Preschool. Combined Modality Therapy. Female. Humans. Infant. Japan / epidemiology. Male. Retrospective Studies. Stem Cell Transplantation. Survival Rate. Young Adult

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2009 Wiley-Liss, Inc.
  • (PMID = 19856396.001).
  • [ISSN] 1545-5017
  • [Journal-full-title] Pediatric blood & cancer
  • [ISO-abbreviation] Pediatr Blood Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


19. Nishiyama H, Tanei R, Motegi T, Ohta M, Sawabe M: Angiotropic B-cell lymphoma with telangiectasia, accompanied by panniculitic formation. J Dermatol; 2004 Dec;31(12):1032-5
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Angiotropic B-cell lymphoma with telangiectasia, accompanied by panniculitic formation.
  • A 67-year-old female presented with diffuse edema, generalized telangiectasia, and indurated skin plaques.
  • Histopathological findings of the skin lesion included CD45+/CD79+/CD20+ large lymphoma cells that filled the vascular lumina and infiltrated the subcutaneous tissues with panniculitic formations.
  • Three cycles of a CHOP (cyclophosphamide, adriamycin, vincristine, and prednisolone) chemotherapy regimen resolved the skin manifestations.
  • After five cycles of CHOP, however, she developed dementia-like symptoms.
  • Three cycles of additional intrathecal chemotherapy (methotrexate, cytarabine and prednisolone) did not improve the neurological symptoms.
  • [MeSH-major] Lymphoma, B-Cell / diagnosis
  • [MeSH-minor] Aged. Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Cyclophosphamide / administration & dosage. Diagnosis, Differential. Doxorubicin / administration & dosage. Edema / etiology. Female. Humans. Immunohistochemistry. Panniculitis / etiology. Prednisone / administration & dosage. Telangiectasis / etiology. Vincristine / administration & dosage

  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15801271.001).
  • [ISSN] 0385-2407
  • [Journal-full-title] The Journal of dermatology
  • [ISO-abbreviation] J. Dermatol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; VB0R961HZT / Prednisone; CHOP protocol
  •  go-up   go-down


20. Chattopadhyay A, Slater DN, Hancock BW: Cutaneous CD56 positive natural killer and cytotoxic T-cell lymphomas. Int J Oncol; 2005 Jun;26(6):1559-62
Hazardous Substances Data Bank. VINCRISTINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cutaneous CD56 positive natural killer and cytotoxic T-cell lymphomas.
  • We report two cases of CD56 positive natural killer (NK) cell and cytotoxic T-cell cutaneous lymphomas and review the literature on these rare forms of non-Hodgkin's lymphoma.
  • The first case was diagnosed to have extra nodal NK/T-cell lymphoma, nasal-type.
  • She had been started on systemic chemotherapy but did not respond.
  • The second case was diagnosed as subcutaneous panniculitis-like T-cell lymphoma, CD56 positive variant.
  • She presented with skin nodules that were quiescent for 10 years.
  • She had systemic chemotherapy and initially had a complete response, but she relapsed within 1 month of completion of chemotherapy.
  • She then had partial response with further chemotherapy but relapsed rapidly.
  • She died within 15 months of her lymphoma changing to its aggressive form.
  • [MeSH-major] Antigens, CD56 / analysis. Killer Cells, Natural / immunology. Lymphoma, T-Cell, Cutaneous / immunology. Skin Neoplasms / immunology. T-Lymphocytes, Cytotoxic / immunology
  • [MeSH-minor] Antineoplastic Combined Chemotherapy Protocols. Cyclophosphamide. Doxorubicin. Female. Humans. Middle Aged. Prednisone. Vincristine

  • Genetic Alliance. consumer health - Cutaneous T-Cell Lymphoma.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15870869.001).
  • [ISSN] 1019-6439
  • [Journal-full-title] International journal of oncology
  • [ISO-abbreviation] Int. J. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Antigens, CD56; 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; VB0R961HZT / Prednisone; CHOP protocol
  •  go-up   go-down


21. Assmann K, Nashan D, Grabbe S, Luger TA, Metze D: [Persistent inflammatory reaction at the injection site of Il-2 with lymphoma-like inflammatory infiltrates]. Hautarzt; 2002 Aug;53(8):554-7
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Persistent inflammatory reaction at the injection site of Il-2 with lymphoma-like inflammatory infiltrates].
  • [Transliterated title] Persistierende knotige Lokalreaktion mit Lymphom-ähnlichen Infiltraten nach s.c-Injektion von Interleukin-2.
  • Interleukin-2 (Il-2) is widely used for treatment of carcinomas, leukemia, and melanoma.
  • Adverse drug effects of Il-2 include various systemic and generalized cutaneous drug reactions.
  • A patient received chemoimmuno-therapy for treatment of metastasizing melanoma, including subcutaneous application of recombinant interleukin-2 (Proleukin((R))).
  • Within a few days reddish nodules developed at the injection sites that persisted after cessation of Il-2 injections for two years until final lethal outcome.
  • Histologic examination revealed a lobular panniculitis expressing atypical lymphocytes and multinucleated histiocytes.
  • [MeSH-major] Drug Eruptions / etiology. Interleukin-2 / adverse effects. Interleukin-2 / analogs & derivatives. Lymphoma, T-Cell, Cutaneous / chemically induced. Melanoma / drug therapy. Recombinant Proteins / adverse effects. Skin Neoplasms / drug therapy
  • [MeSH-minor] Aged. Antigens, CD30 / analysis. Female. Humans. Immunoenzyme Techniques. Injections, Subcutaneous. Neoplasm Metastasis. Palliative Care. Panniculitis / chemically induced. Panniculitis / pathology. Skin / drug effects. Skin / pathology

  • MedlinePlus Health Information. consumer health - Melanoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12221472.001).
  • [ISSN] 0017-8470
  • [Journal-full-title] Der Hautarzt; Zeitschrift für Dermatologie, Venerologie, und verwandte Gebiete
  • [ISO-abbreviation] Hautarzt
  • [Language] ger
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Antigens, CD30; 0 / Interleukin-2; 0 / Recombinant Proteins; M89N0Q7EQR / aldesleukin
  •  go-up   go-down


22. Briki H, Bouaziz JD, Molinier-Frenkel V, Delfau-Larue MH, Ortonne N, Bagot M: Subcutaneous panniculitis-like T-cell lymphoma αβ: complete sustained remission with corticosteroids and methotrexate. Br J Dermatol; 2010 Nov;163(5):1136-8
Hazardous Substances Data Bank. METHOTREXATE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Subcutaneous panniculitis-like T-cell lymphoma αβ: complete sustained remission with corticosteroids and methotrexate.
  • [MeSH-major] Adrenal Cortex Hormones / therapeutic use. Antimetabolites, Antineoplastic / therapeutic use. Lymphoma, T-Cell, Cutaneous / drug therapy. Methotrexate / therapeutic use. Panniculitis / drug therapy. Skin Neoplasms / drug therapy
  • [MeSH-minor] Adolescent. Adult. Aged. Antigens, CD / analysis. Female. Humans. Male. T-Lymphocytes / immunology. Treatment Outcome. Young Adult


23. Michot C, Costes V, Gerard-Dran D, Guillot B, Combes B, Dereure O: Subcutaneous panniculitis-like T-cell lymphoma in a patient receiving etanercept for rheumatoid arthritis. Br J Dermatol; 2009 Apr;160(4):889-90
Hazardous Substances Data Bank. Etanercept .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Subcutaneous panniculitis-like T-cell lymphoma in a patient receiving etanercept for rheumatoid arthritis.
  • [MeSH-major] Anti-Inflammatory Agents, Non-Steroidal / adverse effects. Arthritis, Rheumatoid / drug therapy. Immunoglobulin G / adverse effects. Lymphoma, T-Cell / chemically induced. Skin Neoplasms / chemically induced
  • [MeSH-minor] Etanercept. Female. Humans. Middle Aged. Panniculitis / chemically induced. Receptors, Tumor Necrosis Factor


24. Nakahashi H, Tsukamoto N, Yamane A, Saitoh T, Uchiumi H, Handa H, Karasawa M, Murakami H, Kojima M, Nojima Y: Autologous peripheral blood stem cell transplantation to treat CHOP-refractory aggressive subcutaneous panniculitis-like T cell lymphoma. Acta Haematol; 2009;121(4):239-42
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Autologous peripheral blood stem cell transplantation to treat CHOP-refractory aggressive subcutaneous panniculitis-like T cell lymphoma.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Lymphoma, T-Cell, Cutaneous / surgery. Peripheral Blood Stem Cell Transplantation. Skin Neoplasms / surgery
  • [MeSH-minor] Asparaginase / administration & dosage. Combined Modality Therapy. Cyclophosphamide / administration & dosage. Dexamethasone / administration & dosage. Doxorubicin / administration & dosage. Doxorubicin / analogs & derivatives. Drug Resistance, Neoplasm. Humans. Male. Neoplasm Invasiveness. Panniculitis / diagnosis. Prednisone / administration & dosage. Salvage Therapy. Subcutaneous Tissue. Transplantation, Autologous. Vincristine / administration & dosage. Young Adult






Advertisement